This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hillier, C. J.
Right arrow Articles by Lanar, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hillier, C. J.
Right arrow Articles by Lanar, D. E.

 Previous Article  |  Next Article 

Infection and Immunity, April 2005, p. 2109-2115, Vol. 73, No. 4
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.4.2109-2115.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Process Development and Analysis of Liver-Stage Antigen 1, a Preerythrocyte-Stage Protein-Based Vaccine for Plasmodium falciparum

Collette J. Hillier, Lisa A. Ware, Arnoldo Barbosa, Evelina Angov, Jeffrey A. Lyon, D. Gray Heppner, and David E. Lanar*

Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland

Received 28 September 2004/ Returned for modification 4 November 2004/ Accepted 26 November 2004

Plasmodium falciparum liver-stage antigen 1 (LSA-1) is expressed solely in infected hepatocytes and is thought to have a role in liver schizogony and merozoite release. Specific humoral, cellular, and cytokine immune responses to LSA-1 are well documented, with epitopes identified that correlate with antibody production, proliferative T-cell responses, or cytokine induction. With the goal of developing a vaccine against this preerythrocyte-stage protein, we undertook the good manufacturing practices (GMP) manufacture of a recombinant LSA-1 construct, LSA-NRC, incorporating the N- and C-terminal regions of the protein and two of the centrally placed 17-amino-acid repeats. To improve the protein yield, a method of codon harmonization was employed to reengineer the gene sequence for expression in Escherichia coli. A 300-liter GMP fermentation produced 8 kg of bacterial cell paste, and a three-step column chromatographic method yielded 8 mg of purified antigen per g of paste. The final bulk protein was >98% pure, demonstrated long-term stability, and contained <0.005 endotoxin units per 50 µg of protein. To accomplish the initial stages of evaluation of this protein as a human-use vaccine against malaria, we immunized rabbits and mice with LSA-NRC in Montanide ISA 720. New Zealand White rabbits and A/J (H-2K) mice produced high-titer antibodies that recognized liver-stage parasites in infected cultured human hepatocytes. Gamma interferon-producing cells, which have been associated with LSA-1-mediated protection, were detected in splenocytes harvested from immunized mice. Finally, sera taken from people living in a region where malaria is holoendemic recognized LSA-NRC by Western blotting.

* Corresponding author. Mailing address: Department of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910-7500. Phone: (301) 319-9003. Fax: (202) 318-7594. E-mail: david.lanar{at}na.amedd.army.mil.

Editor: W. A. Petri, Jr.

Infection and Immunity, April 2005, p. 2109-2115, Vol. 73, No. 4
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.4.2109-2115.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez, A., Goudsmit, J., Companjen, A., Mintardjo, R., Gillissen, G., Tax, D., Sijtsma, J., Weverling, G. J., Holterman, L., Lanar, D. E., Havenga, M. J. E., Radosevic, K. (2008). Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1. Infect. Immun. 76: 1709-1718 [Abstract] [Full Text]  
  • Pichyangkul, S., Kum-Arb, U., Yongvanitchit, K., Limsalakpetch, A., Gettayacamin, M., Lanar, D. E., Ware, L. A., Stewart, V. A., Heppner, D. G., Mettens, P., Cohen, J. D., Ballou, W. R., Fukuda, M. M. (2008). Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting of Plasmodium falciparum Liver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates. Infect. Immun. 76: 229-238 [Abstract] [Full Text]  
  • Brando, C., Ware, L. A., Freyberger, H., Kathcart, A., Barbosa, A., Cayphas, S., Demoitie, M.-A., Mettens, P., Heppner, D. G., Lanar, D. E. (2007). Murine Immune Responses to Liver-Stage Antigen 1 Protein FMP011, a Malaria Vaccine Candidate, Delivered with Adjuvant AS01B or AS02A. Infect. Immun. 75: 838-845 [Abstract] [Full Text]  
  • MOORMANN, A. M., JOHN, C. C., SUMBA, P. O., TISCH, D., EMBURY, P., KAZURA, J. W. (2006). STABILITY OF INTERFERON-{gamma} AND INTERLEUKIN-10 RESPONSES TO PLASMODIUM FALCIPARUM LIVER STAGE ANTIGEN-1 AND THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN RESIDENTS OF A MALARIA HOLOENDEMIC AREA. Am J Trop Med Hyg 74: 585-590 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»